CoChat

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Open access
Roddie, Claire, Sandhu, Karamjeet S., Tholouli, Eleni, Logan, Aaron C., Shaughnessy, Paul, Barba, Pere, Ghobadi, Armin, Guerreiro, Manuel, Yallop, Deborah, Abedi, Mehrdad, Pantin, Jeremy M., Yared, Jean A., Beitinjaneh, Amer M., Chaganti, Sridhar, Hodby, Katharine, Menne, Tobias, Arellano, Martha L., Malladi, Ram, Shah, Bijal D., Mountjoy, Luke, O’Dwyer, Kristen M., Peggs, Karl S., Lao-Sirieix, Pierre, Zhang, Yiyun, Brugger, Wolfram, Braendle, Edgar, Pule, Martin, Bishop, Michael R., DeAngelo, Daniel J., Park, Jae H., Jabbour, Elias · 2024 · New England Journal of Medicine
Cited by 241

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. METHODS: We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients with morphologic disease; patients in cohort 2B had measurable residual disease. The primary end point was overall remission (complete remission or complete remission with incomplete hematologic recovery) in cohort 2A. Secondary end points included event-free survival, overall survival, and safety. RESULTS: Of the 153 enrolled patients, 127 (83.0%) received at least one infusion of obe-cel and were evaluable. In cohort 2A (94 patients; median follow-up, 20.3 months), overall remission occurred in 77% (95% confidence interval [CI], 67 to 85), with complete remission in 55% (95% CI, 45 to 66) and complete remission with incomplete hematologic recovery in 21% (95% CI, 14 to 31). The prespecified null hypotheses of overall remission (≤40%) and complete remission (≤20%) were rejected (P<0.001). In the 127 patients who received at least one obe-cel infusion (median follow-up, 21.5 months), the median event-free survival was 11.9 months (95% CI, 8.0 to 22.1); estimated 6- and 12-month event-free survival was 65.4% and 49.5%, respectively. The median overall survival was 15.6 months (95% CI, 12.9 to not evaluable); estimated 6- and 12-month overall survival was 80.3% and 61.1%, respectively. Grade 3 or higher cytokine release syndrome developed in 2.4% of the patients, and grade 3 or higher immune effector cell-associated neurotoxicity syndrome developed in 7.1% of the patients. CONCLUSIONS: Obe-cel resulted in a high incidence of durable response among adults with relapsed or refractory B-cell ALL, with a low incidence of grade 3 or higher immune-related toxic effects. (Funded by Autolus Therapeutics; FELIX ClinicalTrials.gov number, NCT04404660.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2406526

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 241

Metadata

Authors
Roddie, C., Sandhu, K. S., Tholouli, E., Logan, A. C., Shaughnessy, P., Barba, P., Ghobadi, A., Guerreiro, M., Yallop, D., Abedi, M., Pantin, J. M., Yared, J. A., Beitinjaneh, A. M., Chaganti, S., Hodby, K., Menne, T., Arellano, M. L., Malladi, R., Shah, B. D., Mountjoy, L., O’Dwyer, K. M., Peggs, K. S., Lao-Sirieix, P., Zhang, Y., Brugger, W., Braendle, E., Pule, M., Bishop, M. R., DeAngelo, D. J., Park, J. H., & Jabbour, E.
Venue
New England Journal of Medicine
Published
2024-12-12
Volume
391
Issue
23
Pages
2219-2230
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4404784473
Cited by
241
References
1
FWCI
36.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. https://app.cochat.ai/papers/10.1056/nejmoa2406526
The paper
Roddie, C., Sandhu, K. S., Tholouli, E., Logan, A. C., Shaughnessy, P., Barba, P., Ghobadi, A., Guerreiro, M., Yallop, D., Abedi, M., Pantin, J. M., Yared, J. A., Beitinjaneh, A. M., Chaganti, S., Hodby, K., Menne, T., Arellano, M. L., Malladi, R., Shah, B. D., . . . Jabbour, E. (2024). Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2406526

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.